These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 21607712

  • 1. Elevated serum levels of macrophage migration inhibitory factor and their significant correlation with rheumatoid vasculitis disease activity.
    Wakabayashi K, Otsuka K, Sato M, Takahashi R, Odai T, Isozaki T, Yajima N, Miwa Y, Kasama T.
    Mod Rheumatol; 2012 Feb; 22(1):59-65. PubMed ID: 21607712
    [Abstract] [Full Text] [Related]

  • 2. Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis.
    Matsunawa M, Isozaki T, Odai T, Yajima N, Takeuchi HT, Negishi M, Ide H, Adachi M, Kasama T.
    Arthritis Rheum; 2006 Nov; 54(11):3408-16. PubMed ID: 17075825
    [Abstract] [Full Text] [Related]

  • 3. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor.
    Radstake TR, Sweep FC, Welsing P, Franke B, Vermeulen SH, Geurts-Moespot A, Calandra T, Donn R, van Riel PL.
    Arthritis Rheum; 2005 Oct; 52(10):3020-9. PubMed ID: 16200611
    [Abstract] [Full Text] [Related]

  • 4. Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course.
    Llamas-Covarrubias MA, Valle Y, Navarro-Hernández RE, Guzmán-Guzmán IP, Ramírez-Dueñas MG, Rangel-Villalobos H, Estrada-Chávez C, Muñoz-Valle JF.
    Rheumatol Int; 2012 Aug; 32(8):2307-11. PubMed ID: 21607559
    [Abstract] [Full Text] [Related]

  • 5. MIF and TNFα serum levels in rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs: a cross-sectional study.
    Brennan-Bourdon LM, De la Cruz-Mosso U, Reyes-Castillo Z, Martínez-Bonilla GE, Ramírez-Dueñas MG, Islas-Carbajal MC, Rincón-Sánchez AR, Salazar-Páramo M, Muñoz-Valle JF.
    Immunopharmacol Immunotoxicol; 2015 Apr; 37(2):207-13. PubMed ID: 25721154
    [Abstract] [Full Text] [Related]

  • 6. Macrophage migration inhibitory factor upregulates angiogenic factors and correlates with clinical measures in rheumatoid arthritis.
    Kim HR, Park MK, Cho ML, Yoon CH, Lee SH, Park SH, Leng L, Bucala R, Kang I, Choe J, Kim HY.
    J Rheumatol; 2007 May; 34(5):927-36. PubMed ID: 17407222
    [Abstract] [Full Text] [Related]

  • 7. Diagnostic strategy for the assessment of rheumatoid vasculitis.
    Voskuyl AE, Hazes JM, Zwinderman AH, Paleolog EM, van der Meer FJ, Daha MR, Breedveld FC.
    Ann Rheum Dis; 2003 May; 62(5):407-13. PubMed ID: 12695150
    [Abstract] [Full Text] [Related]

  • 8. Relationship between serum levels of macrophage migration inhibitory factor and the activity of antineutrophil cytoplasmic antibody-associated vasculitides.
    Becker H, Maaser C, Mickholz E, Dyong A, Domschke W, Gaubitz M.
    Clin Rheumatol; 2006 May; 25(3):368-72. PubMed ID: 16391884
    [Abstract] [Full Text] [Related]

  • 9. Macrophage migration inhibitory factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis.
    Llamas-Covarrubias MA, Valle Y, Bucala R, Navarro-Hernández RE, Palafox-Sánchez CA, Padilla-Gutiérrez JR, Parra-Rojas I, Bernard-Medina AG, Reyes-Castillo Z, Muñoz-Valle JF.
    Cytokine; 2013 Mar; 61(3):759-65. PubMed ID: 23402792
    [Abstract] [Full Text] [Related]

  • 10. Levels of circulating cellular fibronectin are increased in patients with rheumatoid vasculitis.
    Voskuyl AE, Emeis JJ, Hazes JM, van Hogezand RA, Biemond I, Breedveld FC.
    Clin Exp Rheumatol; 1998 Mar; 16(4):429-34. PubMed ID: 9706423
    [Abstract] [Full Text] [Related]

  • 11. Associations between circulating macrophage migration inhibitory factor (MIF) levels and rheumatoid arthritis, and between MIF gene polymorphisms and disease susceptibility: a meta-analysis.
    Bae SC, Lee YH.
    Postgrad Med J; 2018 Feb; 94(1108):109-115. PubMed ID: 28912189
    [Abstract] [Full Text] [Related]

  • 12. Increased serum levels of macrophage migration inhibitory factor (MIF) in patients with microscopic polyangiitis.
    Kanemitsu H, Matsunawa M, Wakabayashi K, Sato M, Takahashi R, Odai T, Isozaki T, Yajima N, Miwa Y, Kasama T.
    Open Access Rheumatol; 2009 Feb; 1():1-8. PubMed ID: 27789977
    [Abstract] [Full Text] [Related]

  • 13. Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis.
    Maksymowych WP, Naides SJ, Bykerk V, Siminovitch KA, van Schaardenburg D, Boers M, Landewé R, van der Heijde D, Tak PP, Genovese MC, Weinblatt ME, Keystone EC, Zhukov OS, Abolhosn RW, Popov JM, Britsemmer K, van Kuijk AW, Marotta A.
    J Rheumatol; 2014 Nov; 41(11):2104-13. PubMed ID: 25128504
    [Abstract] [Full Text] [Related]

  • 14. A study on soluble intercellular adhesion molecule-1 and selenium in patients with rheumatoid arthritis complicated by vasculitis.
    Witkowska AM, Kuryliszyn-Moskal A, Borawska MH, Hukałowicz K, Markiewicz R.
    Clin Rheumatol; 2003 Dec; 22(6):414-9. PubMed ID: 14677018
    [Abstract] [Full Text] [Related]

  • 15. Development of a novel method to measure macrophage migration inhibitory factor (MIF) in sera of patients with rheumatoid arthritis by combined electrochemical immunosensor.
    Li S, Zhang R, Li P, Yi W, Zhang Z, Chen S, Su S, Zhao L, Hu C.
    Int Immunopharmacol; 2008 Jun; 8(6):859-65. PubMed ID: 18442790
    [Abstract] [Full Text] [Related]

  • 16. Macrophage migration inhibitory factor up-regulates the expression of interleukin-8 messenger RNA in synovial fibroblasts of rheumatoid arthritis patients: common transcriptional regulatory mechanism between interleukin-8 and interleukin-1beta.
    Onodera S, Nishihira J, Koyama Y, Majima T, Aoki Y, Ichiyama H, Ishibashi T, Minami A.
    Arthritis Rheum; 2004 May; 50(5):1437-47. PubMed ID: 15146413
    [Abstract] [Full Text] [Related]

  • 17. Macrophage migration inhibitory factor: a mediator of matrix metalloproteinase-2 production in rheumatoid arthritis.
    Pakozdi A, Amin MA, Haas CS, Martinez RJ, Haines GK, Santos LL, Morand EF, David JR, Koch AE.
    Arthritis Res Ther; 2006 May; 8(4):R132. PubMed ID: 16872482
    [Abstract] [Full Text] [Related]

  • 18. Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumour necrosis factor alpha-neutralising treatments in rheumatoid arthritis.
    Radstake TR, Fransen J, Toonen EJ, Coenen MJ, Eijsbouts AE, Donn R, van den Hoogen FH, van Riel PL.
    Ann Rheum Dis; 2007 Nov; 66(11):1525-30. PubMed ID: 17456524
    [Abstract] [Full Text] [Related]

  • 19. A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis.
    Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S, Ciolkiewicz M.
    Clin Rheumatol; 2006 May; 25(3):314-9. PubMed ID: 16247585
    [Abstract] [Full Text] [Related]

  • 20. Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflammatory function and regulation by glucocorticoids.
    Leech M, Metz C, Hall P, Hutchinson P, Gianis K, Smith M, Weedon H, Holdsworth SR, Bucala R, Morand EF.
    Arthritis Rheum; 1999 Aug; 42(8):1601-8. PubMed ID: 10446857
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.